AstraZeneca bemoans ODAC judgement on use of Lynparza drug for cancer
(Alliance News) - AstraZeneca PLC on Tuesday bemoaned the results of a regulatory meeting held by the US Food & Drug Administration, which suggested its Lynparza prostate cancer treatment should be limited to tumours with a BRCA mutation. Read More